

SUBJECT INDEX TO VOLUME 6

Activin receptor-like kinase	45	Bacterial translocation	146
ALK-1 as	48	Bone remodeling	59
ALK-2 as	48	calcitonin receptor in	62
ALK-3 as	48	osteoblasts in	59
ALK-4 as	49	osteoclasts in	59
ALK-5 as	50	PPR-dependent modulation of	61
ALK-6 as	50	PTH/PTHrP receptor in	61
ALK-7 as	51	role of calcitonin in	59
as drug targets	52	role of parathyroid hormone in	59
clinical implications of	45	Calcitonin (CT)	59
function of	45,48	as therapeutic agent	67
in cancer	52	clinical utility of	64
in disorders related to	53	discovery of small molecule of	70
in renal disorders	53	in bone remodeling	59
in TGF- β /immune function	53	therapeutic utility of	63
regulation of	47	Cancer immunotherapy	223
signal transduction by	45	targeting tumor-related immunosuppression	
structure of	45	for	223
Adenylyl cyclase	239	suppressor cells of myeloid origin in	230
effect of P-site inhibitors	243	Cancer metastasis	18
in drug therapy	239	functional role of tissue inhibitors of MMP	
to regulate cyclic nucleotide signaling	239	(TIMP) in	19
Adjunctive therapy	193	Chemokine	313
pathogenesis-oriented targets for	193	in lupus nephritis	317
role of blocking inflammatory cytokines	194	molecular level of	315
role of blocking signal transduction	194	Chemokine receptors	315
Advanced glycosylated products (AGE)	279	molecular level of	315
actions of	279	Coagulation	175
Anthracyclines	295	applications in clinical practice	179
as intercalators	295	exacerbation of	175
contra cruciform extrusion of	295	Cruciform binding proteins	298
in DNA regulating sequences	295	in genome	298
Arthritic disorders	331	Cruciform extrusion	296
chemokines in	339	role of DNA supercoiling	296
cytokines in inflammatory type	334	temperature/intercalation effects on	299
innate/acquired immune responses in	331	Diabetes mellitus	77
interleukin-1 (IL-1) in	336	American ginseng in	84
interleukin-10 (IL-10) in	338	antioxidants in	77
interleukin-18 (IL-18) in	337	biotin in	83
naturally derived therapeutic agents in	333	carnitine in	77
nuclear factor kappa B (NF- κ B) in	337	cayenne in	84
pathogenesis for	332	chromium in	85
pathophysiology of	331	essential fatty acids in	77
serine proteases/inhibitors in	340	<i>Ginkgo biloba</i> in	84
therapeutic approaches to	333	<i>Gymnema sylvestris</i> in	85
treatment of	331	L-carnitine in	81
tumor necrosis factor alpha (TNF α) in	334	magnesium in	86
viral proteins in	337	manganese in	87
viral serpins in	340	niacin in	82
Atherosclerosis	332	phytochemicals in	77,84
pathogenesis for	332		
AVP-receptor antagonists	252		
applications of	256		
treatment of hyponatremia by	252		
B cells	345		
in SLE	345		

pycnogenol in	85	Hereditary hemorrhagic telangiectasia	52
selenium in	86	Hospital/ICU blood stream infections	210
short-chain fructooligosaccharides (FOS)	82	etiology of	210
trace elements in	77	Human type 10 17 β -hydroxysteroid dehydrogenase	
vanadium in	85,77	(HSD)	95
vitamins in	86	in intracrinology/metabolism of isoleucine/	
vitamin A in	83	fatty acids	95
vitamin B1 in	84	11 β -Hydroxysteroid dehydrogenases	261
vitamin B6 in	84	animal models for	261
vitamin B12 in	84	as drug target in metabolic syndrome	261
vitamin D in	84	expression of	262
zinc in	87	in glaucoma	263
Endogenous proteins	241	in immune system	263
isoform-specific regulation by	241	inhibition of	263
Estrogen	96	pre-receptor control by metabolic activation by ...	261
inactivation of	96	structure function relationships of	264
Extrapulmonary ARDS	214	Hyponatremia	249
pathogenesis of	215	AVP receptor subtypes in	252
treatment of	215	AVP-receptor antagonists in	252
Family C seven transmembrane (7TM) receptors	7	classification of	250
activation of	7	diagnosis of	250
allosteric interactions of	9	treatment of	249,251
biochemical confirmation of	8	V1aR/V2R antagonists in	255
dimerization of	7,10	V2R antagonists in	253
structure of	7	vasopressin-receptor antagonists for	249
Fibrosis	399	Innate immune system	183
role of PDGF receptor kinase inhibitor		receptors for	183
imatinib	399	Insulin like growth factor (IGF)	279
Forskolin	241	antioxidant effects of	279
pharmacological regulation of	241	Interleukin (IL)-6	373
GABA _B receptor dimerization	10	biology of	373
in G-protein coupling	13	Interstitial lung disease (ILD)	409
Glucocorticoid	259	pathogenesis of	410
in CNS	263	treatment of	409
in disease	260	Intestinal barrier	144
induced osteoporosis	264	Intestinal immune system	144
mechanisms of	259	Intestinal microbiota	143
Glutathione	279	Isoleucine metabolism	99
antioxidant effects of	279	inborn error of	99
Grape seed proanthocyanidins	17	LPS-cell interaction	193
as molecular targets for prostate cancer		therapies directed to interfere with	193
prevention by	17	Lupus nephritis	313
effect on expression of MMP <i>in vitro/in vivo</i>		amplification phase of	313
prostate tumor model	21	blockade of chemokine-mediated tissue	
Green tea polyphenols	17	injury in	313
as molecular target for prostate cancer		chemokine receptors in	315
prevention	17	chemokine-related genes in	317
effect on expression of MMP <i>in vitro/in vivo</i>		clinical scenario of	313
prostate tumor model	20	human data of	317

initiation phase of	313	in cancer	365
progression phase of	314	in inflammation	365
pro-inflammatory chemokines in	315	in rheumatoid arthritis (RA)	363
terminal phase of	315	modification transcription activity by P65 phosphorylation	361
treatment with chemokine/chemokine receptor antagonists in	318	p53 tumor suppressor and	366
B Lymphocyte stimulator (BLyS)	351	redox regulation in activation pathways of	361
biology of	351	regulation pathways of	359
Bly/BLyS receptor interactions in	352	Nicotine	279
BLyS/BlyS receptor deficiency in	352	actions of	279
<i>in vivo</i> consequences of	352	Nitric oxide	137,166
overexpression of	352	biology of	166
therapeutic targeting of	351	cardiovascular derangement in sepsis	166
Lymphoid cell	128	chemistry of	166
sex hormone synthesis in	128	in vasopressin/oxytocin release	137
Matrix metalloproteinases (MMP)	17	NO synthases	167
in cancer metastasis	17	Non-classic androgen synthesis pathway	96
role in cancer	18	Oxidation	98
Mesothelioma	271	of branched chain fatty acids	98
angiogenesis in	272	Palindromic sequences-cruciform motifs	297
Metabolic diseases	259	in DNA	297
drug target in	259	Parathyroid hormone (PTH)	59
type 1 11 β -hydroxysteroid dehydrogenase in	259	as therapeutic agents	67
Metabolic sensors	36	clinical utility of	65
agonists of	36	in bone remodeling	59
Mitochondrial NAD(H)-dependent dehydrogenase	95	therapeutic utility of	63
Mononitroso caffeidine	1	Peroxisome proliferator activated receptors (PPARs)	33
mechanism of action of	1	as therapeutic tools in metabolic diseases	33
metabolic transformation of	1	co-activators co-repressors of	35
Neoplasmas	365	in metabolic sensors	33
genetic aberrations of NF- κ B in	365	selective modulators of	33
Neural tube defects	25	Polymyositis/dermatomyositis	409
by ischemia/reperfusion injury	29	interstitial lung disease in patients	409
classification of	26	pathogenesis of	410
epidemiology of	26	prognosis of	409
epoxide hydrolase deficiency in	26	racial differences in	410
folate deficiency in	28	subtypes of ILD	410
folate regulation polymorphisms in	28	therapeutic agents for	411
free radical scavenging enzyme activity in	28	treatment/management of individual patient with	411
pathogenetic theories of	26	Pro-angiogenic factors	271
teratogenicity of valproate in	29	drug targets to	271
Neurosteroids	98	in primary peritoneal mesothelioma	271
metabolism of	98	Prostaglandin E2	383
NF- κ B	359	as anti-inflammatory regulator in RA	385
activation in neoplasms	366	as proinflammatory mediator in RA	384
as central regulator of inflammatory/ immune responses	359	effects of monocyte/dendritic cells	385
as target in treatment of autoimmune diseases/neoplasms	368	effects on fibroblast-like synoviocytes	387
elucidation of biological actions of	369	effects on osteoblastogenesis/bone formation	389
in autoimmunity	365	effects on osteoclastogenesis/bone resorption	388
		effects on T cells	386

in animal models of inflammatory arthritis	390	by microcirculation injury	143
in pathogenesis of human RA	390	campaign for	217
role of bone remodeling in RA	388	cardiovascular dysfunction in	165
Prostate cancer (PC)	17	cell adaptation in	186
epidemiology of	18	coagulation in	175
Prostate tumor	18	coagulation disorders in	175
epidemiology of	18	diagnosis of	218
Pulmonary ards	213	downregulation of fibrinolysis in	176
pathogenesis of	213	effect on heart	166
treatment of	214	effect on kidneys	166
Rheumatic diseases	351,359,373	effect on vessels	165
anti-interleukin-6 receptor antibody therapy in	373	fluid therapy for	218
B lymphocyte stimulator (BLyS) in	351	free radicals in	159
NF- κ B in	359	gender/susceptibility to	127
overexpression in human disease states	354	gene expression in	170
receptors for	352	glucose control in	219
therapeutic neutralization in human disease	355	guanylate cyclase in	168
therapeutic neutralization in murine disease	353	hepatocellular function in	132
Rheumatoid arthritis	379,383	host defense in	151
cytokine network in	379	hypotension/vascular hyporesponsiveness in	167
pathogenesis of	383	immunomodulation/anti-inflammatory effects in	204
role of PGE2/EP receptors in	383	immunosuppression in	156
therapeutic strategy to	383	impairment of neutrophil migration in	153
Rituximab	345	induced acute lung injury/ARDS	219
in SLE	346	induced cell activation in	183
Selective PPAR modulators (SPPARM)	33	inflammatory mediators in	152
AZ 242 as	36	inhibitors of NOS in	167
benzoyl 2 methyl indoles as	41	inotropic effect in	203
farglitazar as	41	inotropic therapy for	218
FK-614 as	41	intracellular signaling in	170
FMOC-L-leucine as	39	lung in	213
L-764406 as	41	mechanisms of action of hypertonic saline	
ligand binding pockets of	35	resuscitation in	201
molecular determinants of	35	methodology/guidelines for treatment of	217
muraglitazar as	39	microcirculatory improvement in	202
non-TZD based α/γ agonists as	39	neuromuscular blockade in	219
NTZpa as	39	neutrophil function in	151
PAT5A as	41	nitric oxide in	165
PPAR γ partial agonists as	39	nitric oxide effectors in	168
ragaglitazar as	38	nitrosothiols in	168,170
TAK-559 as	38	NOS dimerization/co-factor availability for	169
TZD18 as	38	oxidative stress in	160
Sepsis	127,143,151,159,165,175,183,201,213,217	peripheral vasodilation in	203
activated protein C (APC) in	177	plasma volume in	201
after trauma	127	polymorphonuclear neutrophil in	151
amplified host response in	186	potassium channels in	168,170
analgesia in	219	reactive oxygen species in	159,169
antibiotic therapy for	218	reactive nitrogen species/scavengers in	170
anti-coagulation impairment in	177	recombinant human activated protein C	
antithrombin in	178	(rhAPC) for	218
bacterial recognition in	183	redox defenses in sepsis	160
bacterial translocation in	143	redox signaling in	161
blood product administration in	219	redox imbalance in	159
		role of nitric oxide in	153
		role of sex hormones in	128
		sedation in	219
		selective NOS inhibition for	169
		signal molecules in	185
		sources of ROS in	160
		steroids for	218
		therapeutic targets in	169
		tissue factor pathway inhibitor in	179

transcription factors in	170	inducers of IFN-I in	325
vasopressors for	218	mitochondrial dysfunction in	308
Septic shock	137,165,201,217	NF- κ B in	364
antibiotic therapy for	218	nitric oxide in	309
blood product administration in	219	producers of IFN-I in	325
effect on heart	166	rapamycin in	309
effect on kidneys	166	reactive oxygen species in	308
effect on vessels	165	rituximab in	345
endocrine secretion in	138	signaling abnormalities in	305
fluid therapy for	218	signaling through TCR complex in	305
immunomodulation/anti-inflammatory effects in	204	targeting B cells in	345
inotropic effect in	203	targeting IFN-I inducers in	328
inotropic therapy for	218	targeting IFN-I intracellular signaling pathway in	327
mechanisms of action of hypertonic saline		targeting IFN-I/IFNAR in	327
resuscitation in	201	type I interferon as target of	323
methodology/guidelines for treatment of	217	Systemic sclerosis	395,401
microcirculatory improvement in	202	angiotensin II type 1 receptor antagonists in	403
neuroendocrine regulation during	137	angiotensin-converting enzyme (ACE)	
neuro-immune-endocrine mechanisms during	137	inhibitors in	403
oxytocin release in	140	anti fibrotic mediators for	397
peripheral vasodilation in	203	blocking TGF β receptor kinases in	398
plasma volume in	201	blocking Th2-associated interleukins in	397
recombinant human activated protein C		calcium channel blockers in	403
(rhAPC) for	218	endothelin antagonists in	404
role in septic shock	139	immunomodulators for	395
steroids for	218	immunosuppressive drugs in	406
vasopressin release in	139	inhibiting TGF β activation in	398
vasopressors for	218	<i>N</i> -acetylcysteine in	405
Severe sepsis	207	nitric oxide/phosphodiesterase type 5	
epidemiology of	207	inhibitor in	405
in Australia	210	pathogenesis of	402
in Europe	208	prostacyclin analogues in	404
in Latin America	210	statins in	405
in New Zealand	210	stopping inflammatory cell migration in	397
in Untied States	210	targeting B-cells in	397
incidence of severe sepsis in intensive care		targeting fibrosis in	395
units around world	208	targeting innate immunity in	397
population-based studies of	208	targeting T-cells in	395
Sex hormones	131	targeting TGF β in	398
alterations in cardiac function by	131	targeting vascular disease in	401
mechanism of modulation of cardiac function		vascular involvement in	403
following trauma-hemorrhage by	131	Tesaglitazar	36
Shed-membrane microparticles	287	TGF- β superfamily	45
biological significance of	287	ligands of	45
cellular origin of	288	Tocilizumab	374
effect on vascular reactivity	291	clinical studies of	374
generation of	287	in adult-onset's disease (AOSD)	378
in apoptosis/cell activation	287	in Crohn's disease	378
in pathological states	289	in multicentric Castleman's disease (MCD)	374
origin of	287	in RA	376
pro-coagulant properties of	288	in systemic-onset Juvenile idiopathic	
pro-inflammatory properties of	289	arthritis (soJIA)	378
Systemic lupus erythematosus (SLE)	305,323,345,364	Trauma-hemorrhage	128
BAFF (BLYS) in	364	alterations in immune response in	128
BZ-432 in	308	gender-specific immune response to	130
calcium fluxing in	307	hepatocellular function in	132
CD20 in	346	role of sex hormone receptors	130
genetic influences on IFN-I production in	325		
IL-2CREM in	307		

Tumor cells	224	biology of	323
immunosuppressive factors produced by	224	immunomodulatory effects of	323
regulatory T cells (TREG) in	228	in animal models of SLE	325
Type 1 diabetes (T1D)	103	in SLE	324
antiapoptotic targets in	118	pathways of	324
antioxidant targets in	118	producing cells of	324
autoantibodies in	111	signaling pathways of	323
clinical onset of	103,113		
CTLA-4 in	105		
environmental factors in	106	Vascular cell dysfunction	159
gene-gene interaction in	112	in sepsis	159
genetic factors to	103	redox mechanisms of	159
HLA in	104,112	Vascular disease	401
human islet transplantation in	117	Vasculitic disorders	331
immune response targets in	118	chemokines in	339
insulin VNTR in	104	cytokines in inflammatory type	334
metals in	108	innate/acquired immune responses in	331
multiple autoantibodies in	112	interleukin-1 (IL-1) in	336
oxidative stress in	109	interleukin-10 (IL-10) in	338
pesticides in	108	interleukin-18 (IL-18) in	337
predicting clinical onset of	109	naturally derived therapeutic agents in	333
targeting apoptosis in	115	nuclear factor kappa B (NF- κ B) in	337
targeting autoantigen in	115	serine proteases/inhibitors in	340
targeting immune pathology in	116	treatment of	331
targeting ROS in	114	tumor necrosis factor alpha (TNF α) in	334
therapeutic strategies to	114	viral proteins in	337
vaccination in	114	viral serpins in	340
viral infection in	107	Vasopressin	249
xenobiotics in	108	Viral anti-inflammatory reagents	331
xenogeneic cells/stem cells/cell lines in	117		
Type-I interferons (IFN-I)	323		
as therapeutic target	327		